QQ客服 官方微博 反馈留言

	Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
	He, MinKe; Li, QiJiong; Zou, RuHai; Shen, JingXian; Fang, WanQiang; Tan, GuoSheng; Zhou, YuanMin; Wu, XiaoPing; Xu, Li; Wei, Wei
刊名	JAMA oncology
	2019
卷号	5期号:7页码:953-960
ISSN号	2374-2437
DOI	10.1001/jamaoncol.2019.0250
URL标识	查看原文
WOS记录号	WOS:000481511600008
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/5679101
专题	南华大学
作者单位	1.[Xu, Li 2.Guo, RongPing 3.Wei, Wei 4.Zhou, ZhongGuo 5.Shi, Ming 6.He, MinKe 7.Le, Yong 8.Li, QiJiong 9.Chen, MinShan] Sun Yat Sen Univ, Dept Hepatobiliary Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.
推荐引用方式 GB/T 7714	He, MinKe,Li, QiJiong,Zou, RuHai,et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.[J]. JAMA oncology,2019,5(7):953-960.
APA	He, MinKe.,Li, QiJiong.,Zou, RuHai.,Shen, JingXian.,Fang, WanQiang.,...&Shi, Ming*.(2019).Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial..JAMA oncology,5(7),953-960.
MLA	He, MinKe,et al."Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.".JAMA oncology 5.7(2019):953-960.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。